Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)
Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)
Active, not recruiting · NCT03941132 · Registry updated 2025-02-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2) | Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitus | Active, not recruiting | Phase 2 / Phase 3 | 2025-02-24 | NCT03941132 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Janssen, LP | 23 |
| Juvenile Diabetes Research Foundation | 33 |
| University of British Columbia | 284 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| BCDiabetes | Vancouver | Canada | 1 |
| Mount Sinai Hospital/UHN | Toronto | Canada | 1 |